33 completed, 9 unknown, 7 active not recruiting, 6 recruiting. 35 Phase 2, 27 Phase 1, 10 Phase 3.
Follow TAS-102: new trials by email Literature Review of TAS-102 trials Research Report on TAS-102
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer EMB-01, Irinotecan, TAS-102 - Unresectable/Metastatic Colorectal Cancer | Phase 1 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 120 | 2026-09-30 | 2026-10-16 |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan BL-M07D1, Regorafenib, Fruquintinib - Colorectal Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 130 | 2026-08-01 | 2026-08-27 |
| TAS-102 Plus Radiotherapy in Elderly ESCC TAS-102, Radiotherapy - ESCC, TAS 102 | Phase 1 / Phase 2 | Not yet recruiting | Qianfoshan Hospital | 45 | 2025-09-25 | 2025-09-29 |
| Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC Palliative radiotherapy, Iparomlimab and tuvonralimab, TAS-102 - mCRC | Phase 2 | Not yet recruiting | Jinan Central Hospital | 37 | 2025-08-31 | 2025-08-11 |
| A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706 - Hepatocellular Carcinoma (HCC), Second Line Treatment | Phase 2 | Active not recruiting | Sun Yat-sen University | 62 | 2025-08-01 | 2026-04-29 |
| Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial TAS-102, Capecitabine - Rectal Cancer, Rectal Cancer Patients | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 210 | 2025-07-30 | 2026-10-15 |
| Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC Cetuximab, Trifluridine/Tipiracil - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Unknown | Wangxia LV | 26 | 2024-04-01 | 2024-04-23 |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 AZD0901, Ramucirumab+ paclitaxel, Paclitaxel - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Active not recruiting | AstraZeneca | 594 | 2024-03-04 | 2026-10-15 |
| A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study) Trifluridine/Tipiracil - Metastatic Colorectal Cancer | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 200 | 2024-03-01 | 2024-01-08 | |
| Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy Trifluridine/Tipiracil, intensity-modulated radiotherapy - Rectal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 65 | 2024-01-01 | 2025-04-29 |
| Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. Envafolimab, Trifluridine/Tipiracil, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 33 | 2023-11-01 | 2023-10-11 |
| Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Trastuzumab, Trifluridine and Tipiracil Hydrochloride, Tucatinib - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 2 | Withdrawn | Academic and Community Cancer Research United | 2023-10-31 | 2024-09-19 | |
| Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC Regorafenib, Trifluridine/Tipiracil - Metastatic Colorectal Cancer | Phase 2 | Unknown | Fudan University | 101 | 2023-07-01 | 2023-08-01 |
| Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer Surufatinib, TAS-102 - Pancreatic Neoplasms | Phase 2 | Completed | Sun Yat-sen University | 22 | 2023-01-30 | 2025-05-28 |
| A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study favezelimab/pembrolizumab, regorafenib, TAS-102 - Colorectal Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 94 | 2022-06-14 | 2025-11-26 |
| TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy TAS-102 - Colorectal Cancer | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2022-06-06 | 2026-10-01 |
| A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer Nivolumab-relatlimab FDC, Regorafenib, TAS-102 - Colorectal Neoplasms | Phase 3 | Terminated | Bristol-Myers Squibb | 769 | 2022-04-28 | 2026-08-26 |
| TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer Tislelizumab, bevacizumab, TAS-102 - Immunotherapy, Colorectal Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 25 | 2022-04-01 | 2022-08-23 |
| A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer Colorectal Cancer Peptide Vaccine PolyPEPI1018, Trifluridine and Tipiracil Hydrochloride - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Completed | Mayo Clinic | 15 | 2022-01-10 | 2026-10-07 |
Showing 20 of 70. Sign in to see all of them.
Colorectal Neoplasms (36) · Rectal Neoplasms (10) · Colonic Neoplasms (8) · Neoplasm Metastasis (7) · Stomach Neoplasms (4) · Pancreatic Neoplasms (3) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Gallbladder Neoplasms (2) · Neoplasms (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Adenocarcinoma (1) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1)
Taiho Oncology, Inc. (10) · Academic and Community Cancer Research United (4) · Mayo Clinic (4) · Sun Yat-sen University (3) · Taiho Pharmaceutical Co., Ltd. (3) · University of California, Irvine (3) · Fujian Cancer Hospital (2) · Hunan Cancer Hospital (2) · M.D. Anderson Cancer Center (2) · Merck Sharp & Dohme LLC (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University of Florida (2) · AHS Cancer Control Alberta (1) · AbbVie (1) · Astellas Pharma Global Development, Inc. (1)
United States (41) · China (25) · Japan (9) · France (7) · Spain (7) · Germany (6) · Italy (6) · Canada (5) · Czechia (5) · South Korea (5) · Taiwan (5) · United Kingdom (5) · Australia (4) · Poland (4) · Belgium (3)
Amit Mahipal (2) · Farshid Dayyani, MD, PhD (2) · John H Strickler (2) · Alisha Bent, MD (1) · Boon Cher Goh (1) · Charles D Lopez, MD, PhD (1) · Chia-Chi Lin, MD (1) · Christos Fountzilas, MD (1) · Dennie Jones, MD (1) · Dongsheng Zhang, PhD (1) · Drew Rasco, MD (1) · Farshid Dayyani, MD (1)
PMID 19097774, PMID 21319149, PMID 25970050, PMID 27151157, PMID 27208903, PMID 27443414, PMID 27597276, PMID 28445481, PMID 28712102, PMID 29215955, PMID 29274618, PMID 30350179, PMID 30355453, PMID 31600365, PMID 31912801, PMID 32128634, PMID 32308505, PMID 33544407, PMID 34097100, PMID 35738999, PMID 36331676, PMID 36514060, PMID 36622402, PMID 37213030, PMID 37339254, PMID 38084840, PMID 38103947, PMID 38312102, PMID 39232496, PMID 39244627, PMID 39510786, PMID 40341124, PMID 40669021, PMID 41039600, PMID 41781240, PMID 41811823, PMID 42066233
P30CA015083 (5), 2023 (3), 2015 (1), 2018 (1), 2019 (1), P30CA033572 (1), P30CA072720 (1)